First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
2018 · New England Journal of Medicine · 3,395 citations
https://doi.org/10.1056/nejmoa1809064
M
Makoto Nishio
Mie University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
851
Papers
30.8K
Citations
69
h-index
270
i10-index
Makoto Nishio is an academic researcher from Mie University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Research Studies & Lung Cancer Diagnosis and Treatment. The author has an h-index of 69, co-authored 724 publications.
ORCID: 0000-0003-4969-4165Papers by this author
worksDurvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · The Lancet · 2,108 citations
https://doi.org/10.1016/s0140-6736(19)32222-6
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
2014 · The Lancet Oncology · 747 citations
https://doi.org/10.1016/s1470-2045(14)70381-x
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
2020 · Journal of Thoracic Oncology · 430 citations
https://doi.org/10.1016/j.jtho.2020.11.025
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
2021 · Journal of Thoracic Oncology · 318 citations
https://doi.org/10.1016/j.jtho.2021.09.010
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
2023 · Nature Medicine · 127 citations
https://doi.org/10.1038/s41591-023-02226-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat